《自然·医学》新发掘：菌株水平的肠菌特征，为跨癌症免疫治疗供给助力
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="//q9.itc.cn/q_70/images01/20240115/a2f670f1c311486a808c27fc11443374.png" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="//q0.itc.cn/q_70/images01/20240304/53e8c7f04d8046cea7608a79afec22b4.jpeg" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">该篇日报由R·AI辅助创作生成，人工审核校对。</p>
<h1 style="color: black; text-align: left; margin-bottom: 10px;"><strong style="color: blue;">Nature子刊：肠道微生物<span style="color: black;">怎样</span>影响免疫治疗效果？</strong></h1>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Nature Medicine——</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">① 本<span style="color: black;">科研</span><span style="color: black;">经过</span>深入的宏基因组测序技术，<span style="color: black;">发掘</span>了与癌症<span style="color: black;">病人</span>对免疫<span style="color: black;">检测</span>点阻断治疗（ICB）反应<span style="color: black;">关联</span>的肠道微生物特征，为<span style="color: black;">将来</span>的微生物组诊断或治疗<span style="color: black;">供给</span>了新的方向；② 研究<span style="color: black;">显示</span>，与微生物物种相比，菌株水平的微生物丰度，能更好地<span style="color: black;">加强</span><span style="color: black;">设备</span>学习预测ICB反应和12个月<span style="color: black;">没</span><span style="color: black;">发展</span><span style="color: black;">存活</span>期的准确性；③ <span style="color: black;">经过</span>对进一步六项类似<span style="color: black;">科研</span>的宏基因组分析，<span style="color: black;">发掘</span>这些肠道微生物特征在不同癌症（跨癌种）和不同国家（<span style="color: black;">跨境</span>家）中<span style="color: black;">拥有</span><span style="color: black;">广泛</span>有效性，但前提是训练和测试队列<span style="color: black;">运用</span>一致的ICB<span style="color: black;">方法</span>；④ <span style="color: black;">科研</span>强调了<span style="color: black;">按照</span>ICB治疗<span style="color: black;">方法</span>而非癌症类型，来定制肠道微生物组诊断或治疗的<span style="color: black;">要紧</span>性。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">原文信息 ▼</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">A gut microbial signature for combination immune checkpoint blockade across cancer types</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2024-03-01 , doi: 10.1038/s41591-024-02823-z</p>
<h1 style="color: black; text-align: left; margin-bottom: 10px;"><strong style="color: blue;">国内团队：具核梭杆菌仿生载体<span style="color: black;">经过</span>清除乳腺癌中的细菌增效化疗</strong></h1>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Chem——</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">① 苏州大学陈倩团队成功<span style="color: black;">研发</span>具核梭杆菌（Fn）仿生载体，<span style="color: black;">经过</span>清除乳腺癌中的细菌<span style="color: black;">增多</span>化疗疗效；② 瘤内Fn与乳腺癌中Gal-GalNAc的表达密切<span style="color: black;">关联</span>，并促进化疗耐药性；③ 将Fn细胞膜与抗生素装载脂质体融合成功制备纳米载体Colistin-LipoFM，可<span style="color: black;">选取</span>性地清除瘤内Fn，并<span style="color: black;">明显</span><span style="color: black;">加强</span>化疗效果；④ 这种纳米载体还可干扰其他肿瘤内菌群，<span style="color: black;">控制</span>乳腺癌肺转移，并进一步<span style="color: black;">提高</span>标准乳腺癌化疗疗效，且部分小鼠可实现肿瘤的完全消退；⑤ <span style="color: black;">因此呢</span>，Fn仿生纳米载体<span style="color: black;">做为</span>一种优秀的针对细菌定植肿瘤的靶向<span style="color: black;">药品</span>传递载体，为癌症治疗<span style="color: black;">供给</span>了新思路。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">原文信息 ▼</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Fusobacterium nucleatum-mimicking nanovehicles to overcome chemoresistance for breast cancer treatment by eliminating tumor-colonizing bacteria</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2024-02-23 , doi: 10.1016/j.chempr.2024.01.030</p>
<h1 style="color: black; text-align: left; margin-bottom: 10px;"><strong style="color: blue;">秦环龙/蔚青/朱慧媛等Nature子刊：具核梭杆菌促进KRAS p.G12D突变大肠癌的机制</strong></h1>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Nature Communications——</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">① 同济大学秦环龙、蔚青、朱慧媛和团队揭示了具核梭杆菌Fn<span style="color: black;">经过</span>与RNA 解旋酶家族蛋白DHX15结合促进KRAS p.G12D 突变结直肠癌（CRC）的肿瘤<span style="color: black;">发展</span>机制；② Fn在KRAS p.G12D突变CRC肿瘤组织中富集，并促进Villin-Cre/KrasG12D+/-小鼠结直肠肿瘤<span style="color: black;">出现</span>；③ G12D小鼠模型和人类CRC组织中，狄氏副拟杆菌Pd与Fn竞争，口服Pd可减轻Fn依赖性CRC<span style="color: black;">发展</span>；④ 机制上，Fn侵入肠上皮细胞并与CRC肿瘤细胞中ERK/STAT3信号通路介导的的DHX15结合；⑤ Villin-Cre/KrasG12D+/-小鼠中，敲除Dhx15可减轻CRC表型；⑥ 本<span style="color: black;">科研</span>为个性化调节肠道菌群治疗CRC<span style="color: black;">供给</span>了新策略。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">原文信息 ▼</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Fusobacterium nucleatum promotes tumor progression in KRAS p.G12D-mutant colorectal cancer by binding to DHX15</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2024-02-24 , doi: 10.1038/s41467-024-45572-w</p>
<h1 style="color: black; text-align: left; margin-bottom: 10px;"><strong style="color: blue;">崔明/李源等Cell子刊：肠罗斯氏菌或可增敏大肠癌放疗</strong></h1>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Cell Reports——</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">① 中国医学科学院/北京协和医学院放射医学<span style="color: black;">科研</span>所崔明和李源团队揭示了肠道共生菌肠罗斯氏菌<span style="color: black;">经过</span>丁酸盐/OR51E1/RALB轴<span style="color: black;">加强</span>结直肠癌（CRC）对放射治疗的<span style="color: black;">敏锐</span>性，为临床放疗<span style="color: black;">供给</span>了新的增敏策略；② 粪菌移植可<span style="color: black;">引起</span>肠罗斯氏菌在胃肠道中累积，<span style="color: black;">加强</span>CRC放疗疗效而不影响肿瘤<span style="color: black;">出现</span>；③ 原发性和CRC肝转移小鼠模型中，口服肠罗斯氏菌在CRC部位聚集并合成丁酸盐，使CRC对辐射<span style="color: black;">敏锐</span>并减轻肠道毒性；④ 肠罗斯氏菌衍生的丁酸盐可激活CRC<span style="color: black;">病人</span>中过表达的G蛋白偶联受体OR51E1，并促进CRC细胞中的放射性自噬；⑤ 临床直肠癌组织和CRC小鼠模型中，OR51E1与RALB正<span style="color: black;">关联</span>，阻断OR51E1/RALB信号可<span style="color: black;">控制</span>受辐射CRC细胞中丁酸盐<span style="color: black;">诱发</span>的自噬。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">原文信息 ▼</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Roseburia intestinalis sensitizes colorectal cancer to radiotherapy through the butyrate/OR51E1/RALB axis</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2024-02-26 , doi: 10.1016/j.celrep.2024.113846</p>
<h1 style="color: black; text-align: left; margin-bottom: 10px;"><strong style="color: blue;">罕见胰腺肿瘤IPMN中不存在菌群</strong></h1>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Gut——</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">① 纳入190名胰管内乳头状黏液性肿瘤（IPMN）<span style="color: black;">病人</span>和19名阴性对照的338个胰腺囊肿液样本，对其进行16S rRNA测序，检测IPMN中<span style="color: black;">是不是</span>存在可与下一代测序技术的多样性DNA背景区<span style="color: black;">掰开</span>的菌群；② 与阴性对照组相比，胰腺囊肿液样本的菌群特征<span style="color: black;">没</span>差异，<span style="color: black;">没</span>法从<span style="color: black;">归类</span>多样性和微生物群落<span style="color: black;">构成</span>上区分；③ 在<span style="color: black;">近期</span>经历侵入性内窥镜的<span style="color: black;">病人</span>亚组中，<span style="color: black;">显现</span>与肠道<span style="color: black;">关联</span>微生物增加的<span style="color: black;">反常</span>信号，但这一信号并未表现出更高的<span style="color: black;">归类</span>多样性；④ 本<span style="color: black;">科研</span><span style="color: black;">显示</span>胰腺囊性肿瘤为<span style="color: black;">没</span>菌环境，微生物模式与临床或囊肿参数之间<span style="color: black;">没</span><span style="color: black;">显著</span><span style="color: black;">相关</span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">原文信息 ▼</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Absence of a pancreatic microbiome in intraductal papillary mucinous neoplasm</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2024-03-01 , doi: 10.1136/gutjnl-2023-331012</p>
<h1 style="color: black; text-align: left; margin-bottom: 10px;"><strong style="color: blue;">国内团队JAMA子刊：病理组学或助力III期结肠癌<span style="color: black;">病人</span>的<span style="color: black;">精细</span>医疗</strong></h1>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">JAMA Surgery——</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">① 南方医科大学严俊、中山大学王辉与团队<span style="color: black;">发布</span><span style="color: black;">文案</span>，<span style="color: black;">研发</span>并验证了一种基于病理组学的特征，用于预测III期结肠癌患者的预后及化疗效益，为个性化治疗<span style="color: black;">供给</span>了新的依据；② <span style="color: black;">首要</span>从南方医科大学南方医院的数字H-E染色图像中提取了总共114个病理组学特征，利用439名III期结肠癌<span style="color: black;">病人</span><span style="color: black;">构成</span>的训练队列提取出4个特征，构建了一种病理组学的标志物；③ 多变量分析<span style="color: black;">表示</span>，病理组学标志物是与<span style="color: black;">没</span>病<span style="color: black;">存活</span>DFS（HR 2.46）和总<span style="color: black;">存活</span>OS（HR 2.78）<span style="color: black;">关联</span>的独立<span style="color: black;">原因</span>；④ 将病理组学标志物纳入诊断中，在训练和验证队列（n=346）中均表现出比传统模型更好的预测性能；⑤ 进一步分析<span style="color: black;">表示</span>，病理组学标志物得分低的<span style="color: black;">病人</span>更有可能从化疗中获益。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">原文信息 ▼</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Pathomics Signature for Prognosis and Chemotherapy Benefits in Stage III Colon Cancer</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2024-02-28 , doi: 10.1001/jamasurg.2023.8015</p>
<h1 style="color: black; text-align: left; margin-bottom: 10px;"><strong style="color: blue;">徐瑞华/王峰/赵齐等Nature子刊：适用于肿瘤外显子测序数据的ecDNA鉴定新<span style="color: black;">办法</span></strong></h1>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Nature Communications——</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">① 中山大学肿瘤防治中心的徐瑞华、王峰、赵齐<span style="color: black;">做为</span><span style="color: black;">一起</span>通讯在Nature Communications<span style="color: black;">发布</span>最新<span style="color: black;">科研</span>，<span style="color: black;">研发</span>出一种<span style="color: black;">设备</span>学习模型和<span style="color: black;">工具</span>GCAP，用于预测肿瘤基因组中的ecDNA扩增及其<span style="color: black;">关联</span>基因；② ecDNA扩增与微卫星不稳定性（MSI）间存在<span style="color: black;">广泛</span>的互斥模式；③ 在1015名CRC<span style="color: black;">病人</span>队列中，ecDNA扩增被确定为<span style="color: black;">危害</span><span style="color: black;">原因</span>，并有助于细化基因组亚型；④ 四项临床<span style="color: black;">实验</span>数据<span style="color: black;">显示</span>，ecDNA扩增可<span style="color: black;">做为</span>胃肠癌免疫<span style="color: black;">检测</span>点阻断疗法的<span style="color: black;">要紧</span>生物标志物，链接了ecDNA扩增与免疫治疗<span style="color: black;">干涉</span>效果的临床证据。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">原文信息 ▼</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Machine learning-based extrachromosomal DNA identification in large-scale cohorts reveals its clinical implications in cancer</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2024-02-19 , doi: 10.1038/s41467-024-45479-6</p>
<h1 style="color: black; text-align: left; margin-bottom: 10px;"><strong style="color: blue;">Nature子刊：代谢组学<span style="color: black;">设备</span>学习模型可用于胃癌诊断和预后</strong></h1>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Nature Communications——</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">① <span style="color: black;">经过</span>对702个<span style="color: black;">血液</span>样本进行靶向代谢组分析，<span style="color: black;">研发</span>出基于<span style="color: black;">设备</span>学习的胃癌诊断和预后模型，为胃癌的<span style="color: black;">初期</span>检测和<span style="color: black;">精细</span><span style="color: black;">干涉</span><span style="color: black;">供给</span>了新策略；② 构建出<span style="color: black;">包括</span>10种代谢物的胃癌诊断模型，在<span style="color: black;">外边</span>测试集中的<span style="color: black;">敏锐</span>性达到0.905，<span style="color: black;">明显</span>优于传统的依赖癌症蛋白标志物的<span style="color: black;">办法</span>；③ <span style="color: black;">设备</span>学习衍生的预后模型在预测胃癌<span style="color: black;">病人</span><span style="color: black;">危害</span>分层方面，表现优于利用临床参数的传统模型；④ 本<span style="color: black;">科研</span>不仅揭示了胃癌的代谢重编程图谱，还识别出两套不同的生物标志物面板，分别用于<span style="color: black;">初期</span>检测和预后预测，助力胃癌的<span style="color: black;">精细</span>医疗。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">原文信息 ▼</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Metabolomic machine learning predictor for diagnosis and prognosis of gastric cancer</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2024-02-23 , doi: 10.1038/s41467-024-46043-y</p>
<h1 style="color: black; text-align: left; margin-bottom: 10px;"><strong style="color: blue;">南京医科大学：外泌体miR-1246调控肿瘤<span style="color: black;">关联</span>巨噬细胞极化</strong></h1>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Advanced Science——</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">① 南京医科大学的孙跃明和彭雯团队<span style="color: black;">发布</span><span style="color: black;">文案</span>，揭示了外泌体miR-1246在肿瘤<span style="color: black;">关联</span>巨噬细胞(TAMs)极化中的<span style="color: black;">重要</span><span style="color: black;">功效</span>；② 构建共培养系统，使得巨噬细胞的极化过程能够模拟肿瘤免疫微环境中TAMs的<span style="color: black;">繁杂</span>性，<span style="color: black;">发掘</span>外泌体miR-1246能够驱动TAMs的极化，干扰CD8+ T细胞的浸润和功能；③ 外泌体miR-1246的<span style="color: black;">累积</span>是<span style="color: black;">源自</span>于TUT7介导的小非编码RNA的降解，这一过程由SNRPB稳定，而不是<span style="color: black;">源自</span>于miR-1246的前体；④ 外泌体miR-1246含有Exo-基序，能与外泌体分选蛋白hnRNPA2B1结合，<span style="color: black;">经过</span>RNA测序分析<span style="color: black;">发掘</span>，外源性miR-1246在转录后水平调控TAMs的极化，突出了NLRP3在巨噬细胞极化中的<span style="color: black;">重要</span><span style="color: black;">功效</span>；⑤ <span style="color: black;">科研</span>结果不仅强调了外泌体miR-1246在TAMs重编程中的触<span style="color: black;">爆发</span>用，还揭示了其在肿瘤免疫微环境中丰度<span style="color: black;">增多</span>的机制。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">原文信息 ▼</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">The Uridylyl Transferase TUT7-Mediated Accumulation of Exosomal miR-1246 Reprograms TAMs to Support CRC Progression</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2024-02-11 , doi: 10.1002/advs.202304222</p>
<h1 style="color: black; text-align: left; margin-bottom: 10px;"><strong style="color: blue;">新证据！微塑料或能促进肿瘤转移</strong></h1>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Chemosphere——</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">① 本<span style="color: black;">科研</span>揭示了微塑料在人类结直肠癌细胞中的<span style="color: black;">累积</span>及其对细胞迁移和分裂的影响，<span style="color: black;">发掘</span>微塑料可能<span style="color: black;">经过</span><span style="color: black;">加强</span>细胞迁移来促进肿瘤转移；② 0.25、1和10 μm的聚苯乙烯微纳塑料在四种人类结肠癌细胞系中都表现出<span style="color: black;">明显</span>的尺寸和浓度依赖性摄取，其中HCT116细胞摄取速率最高；③ 在细胞分裂过程中，微塑料被母细胞和子细胞共享，且<span style="color: black;">没</span>法被细胞排出；④ 短期暴露于0.25 μm的微塑料<span style="color: black;">明显</span><span style="color: black;">增多</span>了细胞迁移能力，可能促进肿瘤转移；⑤ 塑料颗粒在单层和球形培养中都表现出高度的持久性，在多细胞球体的非增殖部分<span style="color: black;">累积</span>，且不干扰细胞的增殖或分裂。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">原文信息 ▼</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Microplastics role in cell migration and distribution during cancer cell division</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2024-02-27 , doi: 10.1016/j.chemosphere.2024.141463</p>
<h1 style="color: black; text-align: left; margin-bottom: 10px;"><strong style="color: blue;">LISCure活菌药LB-P8治疗PSC 2期临床<span style="color: black;">获准</span></strong></h1>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">① 2月29日，LISCure Biosciences<span style="color: black;">机构</span>宣布，旗下活菌药LB-P8治疗原发性硬化性胆管炎（PSC）的2期临床<span style="color: black;">实验</span>申请<span style="color: black;">得到</span>FDA<span style="color: black;">准许</span>；② LB-P8是一种单菌株活菌药<span style="color: black;">制品</span>，有效<span style="color: black;">成份</span>为嗜柠檬酸明串珠菌（Leuconostoc citreum）菌株，<span style="color: black;">日前</span>已<span style="color: black;">得到</span>FDA授予的治疗PSC孤儿药资格认定；③ PSC是一种罕见的、慢性胆汁淤积性肝病，<span style="color: black;">日前</span><span style="color: black;">无</span><span style="color: black;">获准</span><span style="color: black;">药品</span>，LB-P8有望<span style="color: black;">作为</span>新型治疗手段；④ 在1期临床<span style="color: black;">科研</span>中，LB-P8安全性和耐受性等数据得到确认，首例<span style="color: black;">病人</span>预计将于<span style="color: black;">将来</span>几个月内入组，2025年上半年将<span style="color: black;">颁布</span>该<span style="color: black;">科研</span>的部分顶线结果。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">原文信息 ▼</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">LISCure Biosciences Announces FDA Clearance of IND Application to Initiate a Phase 2 Study of LB-P8 for Primary Sclerosing Cholangitis (PSC)</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2024-02-29 , PR Newswire</p>
<h1 style="color: black; text-align: left; margin-bottom: 10px;"><strong style="color: blue;">治疗罕见病<span style="color: black;">机构</span>「Neurenati Therapeutics」<span style="color: black;">得到</span>120万美元种子融资</strong></h1>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">① 2月29日，Neurenati Therapeutics<span style="color: black;">机构</span>宣布，完<span style="color: black;">成为了</span>由Genson Capital投资的120万美元（约合人民币864万元）种子轮融资；② 融资将用于加速Neurenati Therapeutics<span style="color: black;">机构</span>旗下治疗先天性巨结肠症管线<span style="color: black;">药品</span>NEU-001的临床<span style="color: black;">研发</span>；③ 先天性巨结肠症是一种罕见的胃肠道<span style="color: black;">疾患</span>，在加拿大每年<span style="color: black;">大概</span>100名新生儿<span style="color: black;">病患</span>该病，<span style="color: black;">日前</span>该病治疗手段仅有手术，术后40%的<span style="color: black;">病人</span>会面临<span style="color: black;">各样</span>肠道炎症性<span style="color: black;">疾患</span>；④ Neurenati Therapeutics<span style="color: black;">机构</span>计划在2025年下半年提交NEU-001的新药临床<span style="color: black;">实验</span>申请。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">原文信息 ▼</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Neurenati Therapeutics Concludes a 1.2 Million $ Seed Financing Round to Develop NEU-001 as a Promising Therapy for Hirschsprung Disease</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2024-02-29 , Businesswire</p>
<h1 style="color: black; text-align: left; margin-bottom: 10px;"><strong style="color: blue;">Vivani Medical<span style="color: black;">颁布</span>两项<span style="color: black;">瘦身</span><span style="color: black;">药品</span>临床前<span style="color: black;">科研</span>数据</strong></h1>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">① 2月28日，Vivani Medical<span style="color: black;">机构</span><span style="color: black;">颁布</span>了两项<span style="color: black;">瘦身</span>药临床前<span style="color: black;">科研</span>数据，受此<span style="color: black;">好处</span><span style="color: black;">信息</span>影响，其股价大涨270%；② NPM-115为艾塞那肽皮下<span style="color: black;">移植</span>剂，可实现每年给药2次，PM-139为司美格鲁肽皮下<span style="color: black;">移植</span>剂，可实现每年给药1次；③ 在高脂肪<span style="color: black;">膳食</span>诱导的<span style="color: black;">肥壮</span>小鼠模型上，<span style="color: black;">连续</span>治疗28天后，NPM-115组小鼠的体重相比安慰剂组降低了约20%，与阳性对照司美格鲁肽组相比<span style="color: black;">减肥</span>效果相当；④ 在健康大鼠模型上，<span style="color: black;">连续</span>治疗15周后，NPM-139组大鼠的体重相比安慰剂组降低了约25%，预期效果<span style="color: black;">连续</span>时间为6个月。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">原文信息 ▼</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">一年两次！艾塞那肽<span style="color: black;">移植</span>剂初显<span style="color: black;">减肥</span>实力，GLP-1赛道竞争转向剂型战？</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2024-02-29 , 医药魔方</p>
<h1 style="color: black; text-align: left; margin-bottom: 10px;"><strong style="color: blue;">BioMérieux宣布与FDA达成战略<span style="color: black;">科研</span>合作</strong></h1>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">① 2月28日，诊断<span style="color: black;">制品</span>制造商BioMérieux宣布与FDA达成战略<span style="color: black;">科研</span>合作；② 双方将<span style="color: black;">一起</span><span style="color: black;">研发</span>抗食源性病原体的<span style="color: black;">制品</span>，以改善<span style="color: black;">全世界</span>公共卫生；③ 此次战略合作将开展多个创新项目，旨在优化食品中潜在<span style="color: black;">危害</span>病原体的检测技术和微生物特征分析系统；④ 首批合作项目将基于BioMérieux的xPRO项目进行开展，<span style="color: black;">运用</span>新技术改进产志贺毒素大肠杆菌的分离、降低卡耶塔环<span style="color: black;">胞子</span>虫的检测限，并简化<span style="color: black;">包含</span>沙门氏菌和李斯特菌在内的食源性病原菌的特征分析<span style="color: black;">办法</span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">原文信息 ▼</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">bioMérieux and the Food and Drug Administration Launch Research Collaboration to Improve Microbial Detection Tools to Combat Food-Borne Pathogens</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2024-02-28 , bioMérieux</p>
<h1 style="color: black; text-align: left; margin-bottom: 10px;"><strong style="color: blue;">Lavie Bio<span style="color: black;">得到</span>250万美元里程碑付款</strong></h1>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">① 2月28日，农业微生态<span style="color: black;">机构</span>Lavie Bio宣布，成功<span style="color: black;">得到</span>了Corteva<span style="color: black;">机构</span>支付的第二笔250万美元（约合人民币1799万元）预付款；② 2023年7月，双方签署一项合作协议，Corteva<span style="color: black;">机构</span><span style="color: black;">得到</span>Lavie Bio<span style="color: black;">机构</span>生物一款杀菌剂<span style="color: black;">制品</span>的<span style="color: black;">研发</span>和<span style="color: black;">商场</span>化权利；③ <span style="color: black;">按照</span>协议，Lavie Bio<span style="color: black;">机构</span><span style="color: black;">得到</span>500万美元预付款，<span style="color: black;">将来</span>还将有资格<span style="color: black;">得到</span>生物杀菌剂<span style="color: black;">制品</span><span style="color: black;">营销</span>里程碑付款和提成；④ Lavie Bio是Evogene<span style="color: black;">机构</span>的子<span style="color: black;">机构</span>，致力于<span style="color: black;">经过</span>微生物组技术<span style="color: black;">研发</span>生防菌和促生菌<span style="color: black;">制品</span>，来改善食品质量、可<span style="color: black;">连续</span>性和农业生产力等问题。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">原文信息 ▼</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Lavie Bio Successfully Secures Second Half Advance Payment of $2.5M after Meeting Cortevas Licensing Agreement Requirements</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2024-02-28 , PR Newswire</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">感谢本期日报的审核者：NL，圆圈儿，章台柳，九卿臣，RZN，Richard，lxx<a style="color: black;"><span style="color: black;">返</span></a>回<span style="color: black;">外链论坛：http://www.fok120.com/</span>，查看<span style="color: black;">更加多</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">责任编辑：网友投稿</span></p>
你的努力一定会被看见，相信自己，加油。 大势所趋，用于讽刺一些制作目的就是为了跟风玩梗，博取眼球的作品。 认真阅读了楼主的帖子，非常有益。
页:
[1]